OncoSec Signs Research Agreement with Duke University School of Medicine to Evaluate the Combination of TAVOPLUS with a HER2-Plasmid Vaccine

Shots:

• Duke University to conduct preclinical studies using HER2-plasmid vaccines + TAVO^PLUS (IL-12 plasmids) for HER2+ breast cancer. OncoSec to provide its TAVO and APOLLO (new electroporation generator) to Duke University’s to increase DNA-plasmid cellular transfection rates using lower voltage and a longer pulse width 
• Duke to utilize OncoSec’s TAVO with high-intensity ultrasound tumor ablation models for assessing the impact of IL-12 delivery on the development of systemic immunity
• TAVO (tavokinogene telseplasmid) is immunotherapy enabling intratumoral delivery of DNA-based IL-12, currently being evaluated for metastatic melanoma and triple negative breast cancer. OncoSec is also developing DNA-encoded therapeutic candidates & tumor indications for use with its ImmunoPulse platform

Click here to read full press release/ article | Ref: OncoSec | Image: Twitter